Ultimovacs Updates Timeline for Reporting on Randomized UV1 Phase II Trial INITIUM in Malignant Melanoma; Topline Results expected in March 2024

  Study protocol enables readout of the INITIUM trial after all patients have been followed for a minimum of 18 months, or after 70 patients have progressed or died.As of today, the 70...

Related Keywords

Norway ,Belgium ,Germany ,Oslo ,Vestre Viken Drammen ,Bristol Myers Squibb ,Astrazeneca ,Oslo University Hospital ,Euronext Oslo Stock Exchange ,Halle University ,Carlos De Sousa ,Fast Track ,Orphan Drug ,Vestre Viken ,Drammen Hospital ,Human Leukocyte Antigen ,Markets ,